Pearson has a wide range of Clinical Outcome Assessments (COAs) that measure primary and secondary symptoms related to cognitive/neurocognitive functioning, dementia/Alzheimer's, behavioral and mental health concerns, and other factors affecting a patients’ quality of life. Each has been proven to be reliable through decades of research and is suitable for a wide range of ages with norms reflective of today’s diverse population.
Discover how our COAs are being used in clinical research, access webinars featuring experts in the field, read our blog, or review our newsletter curated with relevant industry-related content.
Growth Scale Values (GSVs) have a long 50-year history within research. However, GSVs are only now gaining traction as an alternative and more precise way to measure outcomes in clinical trials.
read more
In testing and in research, you must have an effective and reliable way to measure change. While raw scores have typically been the go-to for this important role, Growth Scale Values (GSVs) are quickly becoming the preferred method.
Our Director of Pharma Sales, Lynsey Psimas, had the opportunity to speak with Mark Daniel, author of Growth Scale Value (GSV): Theory, Development, and Applications to discuss the importance of GSVs. He spent some time explaining GSVs and their importance in test scoring and pharma research.
read more
featuring Dr. John Harrison
The number of adults living with Alzheimer’s disease (AD) is expected to top 14 million by 2060. Not only is there no cure at this point, but current treatments haven’t been successful, and clinical trials to develop new therapeutic interventions keep failing. What’s holding back novel treatment option breakthroughs? Watch this webinar for insight into why assessment tools fail, strategies for selecting appropriate scales, and how better endpoint measures can help advance AD research.
featuring Dr. Shapiro, Dr. Eisengart, and Dr. Harmatz
Neurogenetic disorders that impact how the brain functions affect up to three percent of children, but available evaluation tools aren’t sensitive enough to detect change in their developmental skills. This poses a challenge for clinical trial sponsors who are trying to assess potential treatments. Gain more expert insight into the difficulties associated with therapy in these trial settings.
